Clearmind Medicine Inc. Updates Corporate Presentation
Ticker: CMND · Form: 6-K · Filed: Aug 20, 2024 · CIK: 1892500
Sentiment: neutral
Topics: corporate-update, filing
TL;DR
Clearmind Medicine Inc. just dropped an updated corporate deck on their website, filed with the SEC.
AI Summary
Clearmind Medicine Inc. filed a Form 6-K on August 20, 2024, to furnish an updated corporate presentation to the SEC. This presentation is incorporated by reference into the report as Exhibit 99.1. The company is a foreign private issuer and files annual reports under Form 20-F.
Why It Matters
Investors can access the latest strategic information and business updates directly from Clearmind Medicine Inc. through this newly filed corporate presentation.
Risk Assessment
Risk Level: low — This filing is a routine update of corporate information and does not contain significant financial or operational news that would inherently increase risk.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the report
- August 20, 2024 (date) — Filing date
- Exhibit 99.1 (document) — Corporate Presentation
- Form 6-K (document) — Type of SEC filing
- Form 20-F (document) — Annual report form for foreign private issuers
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to furnish an updated corporate presentation to the SEC, which is incorporated by reference as Exhibit 99.1.
When was this Form 6-K filed?
This Form 6-K was filed on August 20, 2024.
What is Clearmind Medicine Inc. identified as in this filing?
Clearmind Medicine Inc. is identified as a foreign private issuer.
Which exhibit contains the updated corporate presentation?
Exhibit 99.1 contains the updated corporate presentation.
What type of annual report does Clearmind Medicine Inc. file?
Clearmind Medicine Inc. files its annual reports under cover of Form 20-F.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-08-20 16:15:32
Filing Documents
- ea0211873-6k_clearmind.htm (6-K) — 10KB
- ea021187301ex99-1_clearmind.htm (EX-99.1) — 23KB
- ex99-1_001.jpg (GRAPHIC) — 2201KB
- ex99-1_002.jpg (GRAPHIC) — 2325KB
- ex99-1_003.jpg (GRAPHIC) — 2417KB
- ex99-1_004.jpg (GRAPHIC) — 1847KB
- ex99-1_005.jpg (GRAPHIC) — 2101KB
- ex99-1_006.jpg (GRAPHIC) — 2359KB
- ex99-1_007.jpg (GRAPHIC) — 1625KB
- ex99-1_008.jpg (GRAPHIC) — 1587KB
- ex99-1_009.jpg (GRAPHIC) — 2080KB
- ex99-1_010.jpg (GRAPHIC) — 1375KB
- ex99-1_011.jpg (GRAPHIC) — 1198KB
- ex99-1_012.jpg (GRAPHIC) — 1392KB
- ex99-1_013.jpg (GRAPHIC) — 755KB
- 0001213900-24-071135.txt ( ) — 32068KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: August 20, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3